FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Evo Alemao

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Christopher S Hollenbeak; Lucas E Nikkel; Evo Alemao; Nasrollah Ghahramani; Eric W Schaefer; Jay D Raman
Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
Evo Alemao; Srinivasan Rajagopalan; Shiyi Yang; Rafael E Curiel; Joseph Purvis; Maiwenn J Al
Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.
Hans Keiding; Per Hildebrandt; Evo Alemao; Glenn M Davies
[Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Evo Alemao (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Christopher S Hollenbeak; Lucas E Nikkel; Evo Alemao; Nasrollah Ghahramani; Eric W Schaefer; Jay D Raman
Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
Journal of managed care pharmacy : JMCP 2011;17(8):610-20.
2011: Evo Alemao; Srinivasan Rajagopalan; Shiyi Yang; Rafael E Curiel; Joseph Purvis; Maiwenn J Al
Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.
Journal of medical economics 2011;14(2):245-52.
2008: Hans Keiding; Per Hildebrandt; Evo Alemao; Glenn M Davies
[Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
Ugeskrift for laeger 2008;170(26-32):2323-6.
2008: J Chen; Evo Alemao; D Yin; J Cook
Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.
Diabetes, obesity & metabolism 2008;10 Suppl 1():33-42.
2008: Kenneth K C Lee; Vivian W Y Lee; Wai Kwong Chan; Benjamin S C Lee; Agnes C Y Chong; Jasper C L Wong; Don Yin; Evo Alemao; Brian Tomlinson
Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: results of the Hong Kong hospital audit study.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2008;11 Suppl 1():S91-8.
2007: Srinivasan Rajagopalan; Evo Alemao; Liz Finch; Don Yin
Impact of new Joint British Societies' (JBS 2) guidelines on prevention of cardiovascular disease: evaluation of serum total cholesterol goal achievement in UK clinical practice.
Current medical research and opinion 2007;23(8):2027-34.
2007: Peter Lindgren; Fredrik Borgström; Jan Stålhammar; Evo Alemao; Linus Jönsson
Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs.
International journal of clinical practice 2007;61(8):1410-4.
2007: Lawrence Gould; Glenn M Davies; Evo Alemao; Donald D Yin; John R Cook
Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
Clinical therapeutics 2007;29(5):778-94.
2006: Eric Van Ganse; Thierry Souchet; Laurent Laforest; Philippe Moulin; M Bertrand; Philippe Le-Jeunne; Stephanie Chretin; D Yin; Evo Alemao; G de Pouvourville
Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study.
Atherosclerosis 2006;185(1):58-64.
2006: Kheng-Thye Ho; Khong-Whee Chin; Kheng-Siang Ng; Evo Alemao; Srinivasan Rajagopalan; Don Yin
The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2006;6(6):383-91.
2006: Evo Alemao; Don Yin; Harri Sintonen; Veikko Salomaa; Pekka Jousilahti
Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2006;6(5):349-55.
2006: Michele Kohli; Cheryl Attard; Annette Lam; Daniel Huse; John Cook; Chantal Bourgault; Evo Alemao; Donald Yin; Michael A Marentette
Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.
PharmacoEconomics 2006;24(8):815-30.
2006: Leiv Ose; Finn Egil Skjeldestad; Inger Johanne Bakken; Andree Levorsen; Evo Alemao; Don D Yin; Fredrik Borgström; Linus Jönsson
Lipid management and cholesterol goal attainment in Norway.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2006;6(2):121-8.
2005: Peter Lindgren; Fredrik Borgström; Jan Stålhammar; Evo Alemao; Donald D Yin; Linus Jönsson
Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2005;12(6):530-4.
2005: Eric Van Ganse; Laurent Laforest; Evo Alemao; Glenn Davies; Stephen Gutkin; Don Yin
Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
Current medical research and opinion 2005;21(9):1389-99.
2005: Eric Van Ganse; Thierry Souchet; Laurent Laforest; Philippe Moulin; M Bertrand; Philippe Le-Jeunne; Noemie Travier; D Yin; Evo Alemao; G de Pouvourville
Ineffectiveness of lipid-lowering therapy in primary care.
British journal of clinical pharmacology 2005;59(4):456-63.
2005: Glenn M Davies; John R Cook; John Erbey; Evo Alemao; Enrico Veltri
Projected coronary heart disease risk benefit with ezetimibe.
Atherosclerosis 2005;179(2):375-8.
2005: Karl J Krobot; Donald D Yin; Evo Alemao; Elisabeth Steinhagen-Thiessen
Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2005;12(1):37-45.
2004: Eduardo Meaney; Agustín Vela; Alma Ramos; Evo Alemao; Donald Yin
[Cholesterol goal attainment with lipid lowering drugs. The COMETA Mexico Trial].
Gaceta médica de México 2004;140(5):493-501.
2004: Wim G Goettsch; Donald D Yin; Evo Alemao; Olaf Klungel; Anton F H Stalenhoef; Ron Herings
Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study.
Current medical research and opinion 2004;20(7):1025-33.
2004: John R Cook; Don Yin; Evo Alemao; Glenn Davies; Karl J Krobot; Enrico Veltri; Leslie Lipka; Xavier Badia
Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.
PharmacoEconomics 2004;22 Suppl 3():49-61.
2004: John R Cook; Don Yin; Evo Alemao; Michael Drummond
Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
PharmacoEconomics 2004;22 Suppl 3():37-48.
2004: Asa Carlsson; Fredrik Borgström; Jan Stålhammar; Evo Alemao; Don Yin; Linus Jönsson
Cost of care for patients treated with lipid-lowering drugs.
PharmacoEconomics 2004;22 Suppl 3():25-35.
2003: Ameet Bakhai; Marcus Flather; Julian Collinson; Warren Stevens; Charles Normand; Evo Alemao; Robbin Itzler; Rami Ben-Joseph
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
International journal of cardiology 2003;91(2-3):163-72.
2003: Iren Herjavecz; Gyorgy Boszormenyi Nagy; Kálmán Gyurkovits; Pál Magyar; Karoly Dobos; Laszlo Nagy; Evo Alemao; Rami Ben-Joseph
Cost, morbidity, and control of asthma in Hungary: The Hunair Study.
The Journal of asthma : official journal of the Association for the Care of Asthma 2003;40(6):673-81.
2002: Jean Bousquet; Rami Ben-Joseph; Mark Messonnier; Evo Alemao; Lawrence Gould
A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma.
Clinical therapeutics 2002;24(1):1-20.